BCL-2 Gene Expression and Treatment Response in Follicular Lymphomas
Author Information
Author(s): Soubeyran P, Hostein I, Debled M, Eghbali H, Soubeyran I, Bonichon F, Astier-Gin T, Hœrni B
Primary Institution: Institut Bergonié, Regional Cancer Center
Hypothesis
Can variations in bcl-2/IgH expression during treatment predict the outcome of patients with t(14;18)-bearing follicular lymphomas?
Conclusion
The study found a correlation between bcl-2/IgH expression variations and clinical response to treatment in follicular lymphomas.
Supporting Evidence
- In all but two patients, bcl-2/IgH gene expression was found in pre-treatment samples.
- 47% of treatment phases showed negative bcl-2/IgH expression, with most of these patients responding to chemotherapy.
- Patients with stable bcl-2/IgH-negative conversion had a 100% three-year overall survival rate.
Takeaway
Doctors looked at a gene called bcl-2 in blood samples from lymphoma patients to see if changes in this gene could help predict how well the patients would respond to treatment.
Methodology
The study used reverse transcription polymerase chain reaction (RT-PCR) to analyze 180 serial peripheral blood samples during 34 treatment phases.
Limitations
The study's findings need further confirmation to establish whether bcl-2/IgH expression can predict disease outcome early.
Participant Demographics
Patients with t(14;18)-bearing follicular lymphomas.
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website